Outcome of Patients Sustaining Acute Ischemic Mitral Regurgitation during Myocardial Infarction

Abstract

Objective: To describe outcomes of patients sustaining an acute myocardial infarction complicated by mitral regurgitation managed with contemporary reperfusion therapies.

Design: Inception cohort case study. Long-term follow-up was obtained in 99% of all patients.

Setting: University referral center.

Patients: A series of 1480 consecutive patients presenting between April 1986 and March 1989 who had emergency cardiac catheterization within 6 hours of infarction. Fifty patients were found to have moderately severe or severe mitral regurgitation.

Outcome Measures: Mortality; follow-up cardiac catheterization in patients with regurgitation.

Results: Acute ischemic moderately severe to severe (3 + or 4 +) mitral regurgitation was associated with a mortality of 24% at 30 days (95% Cl, 12% to 36%), 42% at 6 months (Cl, 28% to 56%), and 52% at 1 year (Cl, 38% to 66%); multivariable analysis identified 3 + or 4 + mitral regurgitation as a possible independent predictor of mortality (P = 0.06). Patients with mitral regurgitation tended to be female, older, and to have cerebrovascular disease, diabetes, and preexisting symptomatic coronary artery disease. A physical examination did not identify 50% of patients with moderately severe to severe regurgitation. Acute reperfusion with thrombolysis or angioplasty did not reliably reverse valvular incompetence. In this observational study, the greatest in-hospital and 1-year mortalities were seen in patients reperfused with emergency balloon angioplasty, whereas patients managed medically or with coronary bypass surgery had lower mortalities.

Conclusions: Moderately severe to severe (3 + or 4 +) mitral regurgitation complicating acute myocardial infarction portends a grave prognosis. Acute reperfusion does not reduce mortality to levels experienced by patients with lesser degrees of mitral regurgitation nor does it reliably restore valvular competence.

Article and Author Information

  • From Duke University Medical Center, Durham, North Carolina. For current author addresses, see end of text.

  • Grant Support: In part by grants HL-36587, HL-45702, and HL-17670 from the National Heart, Lung, and Blood Institute, Bethesda, Maryland; grants HS-05635 and HS-06503 from the Agency for Health Care Policy and Research, Rockville, Maryland; grant G08 LM-04613 from the National Library of Medicine, Bethesda, Maryland; and a grant from the Robert Wood Johnson Foundation, Princeton, New Jersey.

  • Requests for Reprints: James E. Tcheng, MD, Box 3275, Duke University Medical Center, Durham, NC 27710.

  • Current Author Addresses: Dr. Tcheng: Box 3275, Duke Medical Center, Durham, NC 27710.

    Dr. Jackman: Box 31136, Duke Medical Center, Durham, NC 27710. Ms. Nelson and Ms. Gardner: Box 3850, Duke Medical Center, Durham, NC 27710.

    Dr. Smith: Box 3391, Duke Medical Center, Durham, NC 27710.

    Dr. Rankin: Box 0118, UCSF Medical Center, 505 Parnaussus, San Francisco, CA 94104.

    Dr. Califf: Box 31123, Duke Medical Center, Durham, NC 27710.

    Dr. Stack: Box 3111, Duke Medical Center, Durham, NC 27710.

| Table of Contents
Most Read Most Read
Most Commented Most Commented On
Annals in the News Annals in the News
Clinical Trials Clinical Trials
Comparative Effectiveness Comparative Effectiveness
Hospital Medicine Hospital Medicine
  • Advertisement
  • Advertisement